Most anti-angiogenic agents are reported to improve in response rate, but not progression-free survival or overall survival compared to chemotherapy alone.
Only ramucirumab has been demonstrated to improve outcome as secondary-line treatment in advance gastric cancer.
Searching robust biological predictors (biomarkers) to stratify patients.